Acute subjective effects of dynorphin A(1-13)) infusion in normal healthy subjects

Drug and Alcohol Dependence

Volumn 54, Issue 1, 1999, Pages 87-90

  King, Andrea C ^a,b   Ho, Ann ^a   Schluger, James ^a   Borg, Lisa ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Agonist; Dynorphin; Opioid; Subjective effects

Indexed keywords

DYNORPHIN[1-13];

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOOD; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFFECT; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; PEPTIDE FRAGMENTS; SINGLE-BLIND METHOD;

EID: 0033008949     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(98)00150-1     Document Type: Article

References (15)

1. 1-13 elevates serum prolactin levels by an opioid receptor mechanism: controlled studies of normal volunteers. In: Harris, L.S. ed., Problems of Drug Dependence, Proc. 59th Annu. Sci. Meet. of the College on Problems of Drug Dependence. NIDA Monograph 178, pp. 167.
2. Brahen, L.S., Capone, T., Wiechert, V., Desiderio, D., 1977. Naltrexone and cyclazocine: a controlled treatment study. Arch. Gen. Psychiatry 34, 1181-1184.
3. 1-13 biotransformation in human and rhesus monkey blood and antinociception. In: Harris, L.S. (Ed.), Problems of Drug Dependence, Proc. 58th Annu. Sci. Meet. of the College on Problems of Durg Dependence. NIDA Monograph, 162, pp. 225.
4. (1-13) peptides in human blood, ex vivo. Peptides 17, 983-990.
5. Greenwald, M.K., Stitzer, M.L., Haberny, K.A., 1997. Human pharmacology of the opioid neuropeptide dynorphin A(1-13). J. Pharmacol. Exp. Ther. 281, 1154-1163.
6. Hooke, L.P., He, L., Lee, N.M., 1995. [Des-Tyr] Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther. 273, 802-807.
7. 1-13 in opioid-treated patients with chronic pain. Abstract for 8th World Congress on Pain.
8. Kreek, M.J., Ho, A., Borg, L., 1994. Dynorphin A(1-13) administration causes elevation of serum levels of prolactin in human subjects. In: Harris, L.S. (Ed.), Problems of Drug Dependence, Proc. 56th Annu. Sci. Meet. of the College on Problems of Durg Dependence. NIDA Monograph, 141, pp. 108.
9. Reece, P.A., Allen, A.J., Rose, S., Wright, S., Dawkins, R., Rajagopalan, R., 1994. Diuretic effects, pharmacokinetics, and safety of a new centrally-acting kappa-opioid agonist (CI-977) in humans. J. Clin. Pharmacol. 34, 1126-1132.
10. Spanagal, R., Herz, A., Shippenburg, T.S., 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. 89, 2046-2050.
11. Specker, S., Wananukul, W., Hatsukami, D. et al., 1998. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology 137, 326-332.
12. Takemori, A.E., Lo, H.H., Lee, N.M., 1993. Suppression by Dyn A and [Des-Tyr] dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266, 121-124.
13. Uneklabh, T., Sintavanarong, P., Wessagowit, V., Lukanapichonchut, L., 1995. Clinical effect of dynorphin on heroin addicts. J. Med. Assoc. Thail. 78, 509-516.
14. Ur, E., Wright, D.M., Bouloux, P.M., Grossman, A., 1997. The effects of spiradoline (U-62066E), a κ -opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120, 781-784.
15. Wen, H.L., Ho, W.K.K., Wen, P.Y.C., 1984. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100, 155-162.